Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study
BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. METHODS AND RESULTS—The Bruneck study is a prospective population-based...
Saved in:
Published in | Arteriosclerosis, thrombosis, and vascular biology Vol. 27; no. 8; pp. 1788 - 1795 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Heart Association, Inc
01.08.2007
Hagerstown, MD Lippincott |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known.
METHODS AND RESULTS—The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors.
CONCLUSIONS—This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB. |
---|---|
AbstractList | BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known.
METHODS AND RESULTS—The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors.
CONCLUSIONS—This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB. Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known.BACKGROUNDOxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known.The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors.METHODS AND RESULTSThe Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors.This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB.CONCLUSIONSThis study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB. Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors. This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB. Background— Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. Methods and Results— The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P =0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity ( P =0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors. Conclusions— This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB. Oxidized phospholipids (OxPL) detected by monoclonal antibody E06 (OxPL/apoB), lipoprotein(a), and Lp-PLA2 activity were measured in the Bruneck Study, where 82 of 765 subjects developed cardiovascular events over 10 years. OxPL/apoB and Lp(a) predicted 10-year cardiovascular events independently of traditional risk factors, hsCRP, and the Framingham risk score. Increasing Lp-PLA2 activity further amplified the risk mediated by OxPL/apoB and Lp(a). |
Author | Kiechl, Stefan Tsimikas, Sotirios Mayr, Manuel Kronenberg, Florian Viehweider, Brigitte Oberthaler, Sabine Wiedermann, Christian J. Oberhollenzer, Martin Xu, Qingbo Willeit, Johann Witztum, Joseph L. |
AuthorAffiliation | From the Department of Neurology (S.K., J.W.), the Division of General Internal Medicine (C.J.W., S.O., B.V., M.O.), and the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology (F.K.), Medical University of Innsbruck, Austria; the Cardiovascular Division (Q.X., M.M.), King’s College London, University of London, UK; and the Department of Medicine (J.L.W., S.T.), University of California San Diego, La Jolla |
AuthorAffiliation_xml | – name: From the Department of Neurology (S.K., J.W.), the Division of General Internal Medicine (C.J.W., S.O., B.V., M.O.), and the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology (F.K.), Medical University of Innsbruck, Austria; the Cardiovascular Division (Q.X., M.M.), King’s College London, University of London, UK; and the Department of Medicine (J.L.W., S.T.), University of California San Diego, La Jolla |
Author_xml | – sequence: 1 givenname: Stefan surname: Kiechl fullname: Kiechl, Stefan organization: From the Department of Neurology (S.K., J.W.), the Division of General Internal Medicine (C.J.W., S.O., B.V., M.O.), and the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology (F.K.), Medical University of Innsbruck, Austria; the Cardiovascular Division (Q.X., M.M.), King’s College London, University of London, UK; and the Department of Medicine (J.L.W., S.T.), University of California San Diego, La Jolla – sequence: 2 givenname: Johann surname: Willeit fullname: Willeit, Johann – sequence: 3 givenname: Manuel surname: Mayr fullname: Mayr, Manuel – sequence: 4 givenname: Brigitte surname: Viehweider fullname: Viehweider, Brigitte – sequence: 5 givenname: Martin surname: Oberhollenzer fullname: Oberhollenzer, Martin – sequence: 6 givenname: Florian surname: Kronenberg fullname: Kronenberg, Florian – sequence: 7 givenname: Christian surname: Wiedermann middlename: J. fullname: Wiedermann, Christian J. – sequence: 8 givenname: Sabine surname: Oberthaler fullname: Oberthaler, Sabine – sequence: 9 givenname: Qingbo surname: Xu fullname: Xu, Qingbo – sequence: 10 givenname: Joseph surname: Witztum middlename: L. fullname: Witztum, Joseph L. – sequence: 11 givenname: Sotirios surname: Tsimikas fullname: Tsimikas, Sotirios |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18940235$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17541022$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAURiNURH_gBVggb0AgNYPt2HHCLh1RWmmkqaAgsYoc50YxdeLUdlqGN-ItcTUDVVl0ZV_pnCvd7ztM9kY7QpK8JHhBSE7eV5ffTqqzakGwWBDGC8yfJAeEU5ayPMv34h-LMuU5o_vJofc_MMaMUvws2SeCM4IpPUh-r3_qVv-CFl301k-9NXrSrT9GKz3ZydkAenwr3z2Y08p7q7QMDyzpAVUUVSroGx02x0iOLSI4_Q7SoaV0rbY30qvZxHE9B2UH8B_QhYs-3DmAPoOfTfDo1NkBhR7QiZtHUFfoS5jbzfPkaSeNhxe79yj5evrxcnmWrtafzpfVKlWMUJ52nWIFybAoZNmQThY8w0Wel7QpccFIR0SDOe5KRUgjOImRtJwWESFMlpRDdpS82e6N117P4EM9aK_AGDmCnX0tsOAUFyKCr3bg3AzQ1pPTg3Sb-m-4EXi9A-Ld0nROjkr7e64oGaYZj1yx5VQMwzvoaqWDDNqOwUltaoLru77rXd9xFvW276jS_9R_2x-T8q10a00A56_MfAuu7kGa0D8m_gHPl78k |
CODEN | ATVBFA |
CitedBy_id | crossref_primary_10_2217_clp_11_72 crossref_primary_10_17116_kardio20158349_52 crossref_primary_10_1016_j_atherosclerosis_2024_117474 crossref_primary_10_1016_j_phrs_2017_02_001 crossref_primary_10_2217_clp_13_13 crossref_primary_10_1111_eci_13710 crossref_primary_10_1016_j_jacl_2022_10_004 crossref_primary_10_1016_j_cjca_2017_07_015 crossref_primary_10_2217_bmm_11_60 crossref_primary_10_1093_ije_dyp273 crossref_primary_10_1016_j_atherosclerosis_2009_09_077 crossref_primary_10_1194_jlr_M012526 crossref_primary_10_1007_s11033_010_0529_9 crossref_primary_10_1016_j_atherosclerosis_2011_09_019 crossref_primary_10_1080_10408363_2016_1188055 crossref_primary_10_1007_s11936_008_0047_4 crossref_primary_10_1016_j_amjcard_2008_04_015 crossref_primary_10_1016_j_jacc_2009_12_048 crossref_primary_10_1016_j_jacc_2013_09_042 crossref_primary_10_1016_j_amjcard_2008_04_018 crossref_primary_10_1016_j_ijcard_2013_01_182 crossref_primary_10_3389_fcvm_2024_1470364 crossref_primary_10_1016_j_jacl_2020_12_002 crossref_primary_10_1093_eurheartj_ehn502 crossref_primary_10_1016_j_amjcard_2009_09_052 crossref_primary_10_1016_j_jacl_2024_04_133 crossref_primary_10_1038_s41569_023_00937_4 crossref_primary_10_1093_hmg_ddw211 crossref_primary_10_1042_CS20080486 crossref_primary_10_1007_s12181_008_0065_1 crossref_primary_10_1016_j_jacl_2011_08_004 crossref_primary_10_1016_j_jicc_2014_08_004 crossref_primary_10_1016_j_plipres_2017_09_001 crossref_primary_10_1007_s10557_008_6133_8 crossref_primary_10_1007_s12170_010_0153_1 crossref_primary_10_1016_j_jacc_2016_11_042 crossref_primary_10_1016_j_amjcard_2008_04_014 crossref_primary_10_1016_j_jclinepi_2017_12_017 crossref_primary_10_1194_jlr_R024190 crossref_primary_10_1155_2012_480784 crossref_primary_10_1007_s11936_017_0549_z crossref_primary_10_1016_j_jacc_2007_11_087 crossref_primary_10_1097_HCO_0b013e32832ac21a crossref_primary_10_1007_s11883_008_0048_5 crossref_primary_10_1111_j_1460_9568_2009_06983_x crossref_primary_10_1093_hmg_ddp424 crossref_primary_10_1016_j_jprot_2011_07_008 crossref_primary_10_1155_2011_418313 crossref_primary_10_1016_j_atherosclerosis_2012_06_020 crossref_primary_10_1194_jlr_P027235 crossref_primary_10_1007_s10157_013_0875_8 crossref_primary_10_1194_jlr_M040733 crossref_primary_10_1097_MOL_0b013e3282fe1d0e crossref_primary_10_1016_j_atherosclerosis_2008_04_036 crossref_primary_10_1111_echo_70061 crossref_primary_10_1007_s11883_013_0360_6 crossref_primary_10_1194_jlr_R067314 crossref_primary_10_1016_j_neubiorev_2021_06_017 crossref_primary_10_1016_j_jacc_2007_11_079 crossref_primary_10_1042_BCJ20240037 crossref_primary_10_1016_j_freeradbiomed_2008_04_013 crossref_primary_10_1186_s12263_019_0658_2 crossref_primary_10_1016_j_jacc_2016_10_057 crossref_primary_10_1097_MOL_0b013e32832fa58d crossref_primary_10_1016_j_pharmthera_2010_01_008 crossref_primary_10_3109_07853890_2011_582511 crossref_primary_10_2174_1568026623666230502140614 crossref_primary_10_1073_pnas_1800544115 crossref_primary_10_1161_ATVBAHA_115_305306 crossref_primary_10_18087_cardio_2019_12_n727 crossref_primary_10_1016_j_jacc_2013_08_1639 crossref_primary_10_1194_jlr_M060210 crossref_primary_10_1016_j_jacc_2012_08_979 crossref_primary_10_1007_s12263_011_0217_y crossref_primary_10_1016_j_jacc_2008_02_066 crossref_primary_10_1194_jlr_M005769 crossref_primary_10_1080_07853890902769675 crossref_primary_10_1194_jlr_M800342_JLR200 crossref_primary_10_1186_s12944_017_0476_8 crossref_primary_10_1016_j_atherosclerosis_2009_12_036 crossref_primary_10_1016_j_jacc_2008_01_026 crossref_primary_10_1007_s10557_016_6648_3 crossref_primary_10_1155_2013_714653 crossref_primary_10_1016_j_jacc_2011_12_033 crossref_primary_10_3390_ijms24010170 crossref_primary_10_1016_j_jacc_2013_12_030 crossref_primary_10_1172_JCI63108 crossref_primary_10_1097_MOL_0b013e328308b622 crossref_primary_10_1016_j_coph_2013_02_005 crossref_primary_10_1016_j_jacc_2012_04_038 crossref_primary_10_1161_JAHA_120_015878 crossref_primary_10_1016_j_clinbiochem_2010_01_013 crossref_primary_10_1016_j_atherosclerosis_2022_10_002 crossref_primary_10_2217_clp_09_74 crossref_primary_10_2337_dc08_0349 crossref_primary_10_1007_s10557_015_6634_1 crossref_primary_10_1016_j_jacc_2007_11_051 crossref_primary_10_1097_MOL_0b013e3283598d81 crossref_primary_10_1021_acsmedchemlett_6b00281 crossref_primary_10_2217_14796678_5_2_159 crossref_primary_10_1016_j_atherosclerosis_2010_03_021 crossref_primary_10_3109_10408363_2014_992063 crossref_primary_10_1016_j_atherosclerosis_2022_04_001 crossref_primary_10_1016_j_numecd_2022_05_013 crossref_primary_10_3109_0886022X_2013_774680 crossref_primary_10_1007_s11883_010_0095_6 crossref_primary_10_1172_JCI58969 crossref_primary_10_3390_ijms24032237 crossref_primary_10_1194_jlr_P030890 crossref_primary_10_1016_j_clinbiochem_2012_03_031 crossref_primary_10_1016_j_jacc_2010_04_048 crossref_primary_10_1016_j_jacc_2023_02_051 crossref_primary_10_1007_s10557_008_6135_6 crossref_primary_10_1097_HCO_0000000000000300 crossref_primary_10_1097_MOL_0b013e328306f0cc crossref_primary_10_1186_s12872_015_0001_9 crossref_primary_10_1016_j_pcad_2016_07_005 crossref_primary_10_1016_j_freeradbiomed_2012_08_004 crossref_primary_10_4155_bio_2019_0280 crossref_primary_10_3390_ijms25020736 crossref_primary_10_1039_C5FO00362H crossref_primary_10_1007_s00431_023_04935_z crossref_primary_10_1016_j_ijcard_2010_08_008 crossref_primary_10_1016_j_atherosclerosis_2008_10_040 crossref_primary_10_1016_j_jacl_2011_07_005 crossref_primary_10_1139_cjpp_2018_0490 crossref_primary_10_1161_JAHA_123_031825 crossref_primary_10_1186_1476_511X_13_59 crossref_primary_10_1038_s41569_018_0153_2 crossref_primary_10_1016_j_jacl_2012_01_004 crossref_primary_10_1089_ars_2009_2597 crossref_primary_10_1007_s12265_014_9590_4 crossref_primary_10_1194_jlr_M800174_JLR200 crossref_primary_10_3310_hta191000 crossref_primary_10_1161_ATVBAHA_113_301297 crossref_primary_10_5551_jat_6585 crossref_primary_10_1586_erc_12_32 crossref_primary_10_1016_j_jacc_2013_02_047 crossref_primary_10_1007_s12170_022_00698_8 crossref_primary_10_1016_j_freeradbiomed_2012_05_031 crossref_primary_10_1038_s41598_017_16464_5 crossref_primary_10_1016_j_jacc_2015_07_020 crossref_primary_10_1016_j_jacl_2016_01_005 crossref_primary_10_1258_cvd_2012_012011 crossref_primary_10_1186_1476_511X_10_170 crossref_primary_10_1016_j_thromres_2011_07_001 crossref_primary_10_1007_s11886_013_0417_8 crossref_primary_10_3390_ph3051360 crossref_primary_10_1007_s11883_012_0266_8 crossref_primary_10_1097_HCO_0b013e32832bcb22 crossref_primary_10_1016_j_amjcard_2008_02_006 crossref_primary_10_2217_bmm_2016_0096 crossref_primary_10_1007_s11239_016_1351_6 crossref_primary_10_4061_2011_156326 crossref_primary_10_1016_j_ijcard_2012_09_210 crossref_primary_10_1016_j_atherosclerosis_2008_08_045 crossref_primary_10_1002_biof_1890 crossref_primary_10_1007_s11883_008_0036_9 crossref_primary_10_1186_1476_511X_13_41 crossref_primary_10_1111_j_1365_2796_2012_02592_x crossref_primary_10_1038_s41598_021_95141_0 crossref_primary_10_2217_17584299_4_1_41 crossref_primary_10_1186_1476_511X_11_4 crossref_primary_10_1253_circj_CJ_09_0924 crossref_primary_10_1016_j_cdtm_2017_02_008 crossref_primary_10_1007_s11892_019_1246_y crossref_primary_10_1016_j_jacc_2009_02_041 crossref_primary_10_3390_molecules28030969 crossref_primary_10_1007_s11789_017_0090_3 crossref_primary_10_1194_jlr_R052258 crossref_primary_10_1194_jlr_E060947 crossref_primary_10_1016_j_jacc_2011_10_881 crossref_primary_10_1080_14737159_2017_1352472 crossref_primary_10_1194_jlr_R800074_JLR200 |
Cites_doi | 10.1016/j.jacc.2005.02.058 10.1016/j.jacc.2006.03.024 10.1161/circ.102.10.1082 10.1111/j.1399-0004.1997.tb04342.x 10.1001/jama.1986.03380180102027 10.1016/0021-9150(96)05872-8 10.1016/S0092-8674(01)00238-0 10.1093/ajcn/36.5.936 10.1161/atvb.19.6.1484 10.1016/S0002-9149(96)00159-2 10.1016/j.cll.2006.06.003 10.1161/01.cir.0000141728.23033.b5 10.1161/circulationaha.104.529297 10.1016/j.jacc.2006.03.001 10.1016/S1567-5688(02)00045-4 10.1056/NEJMoa043175 10.1001/jama.296.11.1363 10.1056/NEJMoa001066 10.1016/S0735-1097(02)02769-9 10.1016/j.atherosclerosis.2004.01.029 10.1194/jlr.M600109-JLR200 10.1161/circ.100.11.1154 10.1016/j.atherosclerosis.2004.07.030 10.1194/jlr.R400001-JLR200 10.1016/S0009-8981(00)00216-3 10.1016/j.jacc.2005.12.047 10.1016/j.cll.2006.06.004 10.1161/01.cir.0000130844.01174.55 10.1056/NEJMra043430 10.1074/jbc.270.52.31151 10.1093/clinchem/36.1.20 |
ContentType | Journal Article |
Copyright | 2007 American Heart Association, Inc. 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 American Heart Association, Inc. – notice: 2007 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/ATVBAHA.107.145805 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4636 |
EndPage | 1795 |
ExternalDocumentID | 17541022 18940235 10_1161_ATVBAHA_107_145805 10.1161/ATVBAHA.107.145805 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: HL56989 |
GroupedDBID | --- .3C .55 .GJ .Z2 01R 0R~ 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACGOD ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFFNX AFUWQ AGINI AHJKT AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BOYCO BQLVK BS7 C1A C45 CS3 DIK DIWNM DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ PZZ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W X7M XXN XYM YFH ZGI ZZMQN AAYXX ADGHP CITATION IQODW ACIJW AWKKM CGR CUY CVF ECM EIF NPM OK1 OLW RHF 7X8 |
ID | FETCH-LOGICAL-c4125-ffc4813078a9b1fa853086692b90841f17b050f9c11b751004d52808614a925e3 |
ISSN | 1079-5642 1524-4636 |
IngestDate | Fri Jul 11 16:58:53 EDT 2025 Wed Feb 05 09:37:54 EST 2025 Mon Jul 21 09:14:58 EDT 2025 Tue Jul 01 02:21:24 EDT 2025 Thu Apr 24 23:01:48 EDT 2025 Fri May 16 03:46:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Prognosis Enzyme Phospholipid Cardiovascular disease Esterases Phospholipase A lipoprotein-associated phospholipase A2 Lipoprotein a Carboxylic ester hydrolases lipoprotein (a) Vascular disease Atherosclerosis Hydrolases Oxidation oxidized phospholipids lipoproteins |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4125-ffc4813078a9b1fa853086692b90841f17b050f9c11b751004d52808614a925e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17541022 |
PQID | 70752087 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_70752087 pubmed_primary_17541022 pascalfrancis_primary_18940235 crossref_citationtrail_10_1161_ATVBAHA_107_145805 crossref_primary_10_1161_ATVBAHA_107_145805 wolterskluwer_health_10_1161_ATVBAHA_107_145805 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-August |
PublicationDateYYYYMMDD | 2007-08-01 |
PublicationDate_xml | – month: 08 year: 2007 text: 2007-August |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA Hagerstown, MD |
PublicationPlace_xml | – name: Philadelphia, PA – name: Hagerstown, MD – name: United States |
PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
PublicationYear | 2007 |
Publisher | American Heart Association, Inc Lippincott |
Publisher_xml | – name: American Heart Association, Inc – name: Lippincott |
References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 (e_1_3_3_10_2) 2004; 25 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_32_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_31_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_1_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_3_2 doi: 10.1016/j.jacc.2005.02.058 – volume: 25 start-page: e71. year: 2004 ident: e_1_3_3_10_2 publication-title: Arterioscler Thromb Vasc Biol – ident: e_1_3_3_13_2 doi: 10.1016/j.jacc.2006.03.024 – ident: e_1_3_3_20_2 doi: 10.1161/circ.102.10.1082 – ident: e_1_3_3_26_2 doi: 10.1111/j.1399-0004.1997.tb04342.x – ident: e_1_3_3_22_2 doi: 10.1001/jama.1986.03380180102027 – ident: e_1_3_3_30_2 doi: 10.1016/0021-9150(96)05872-8 – ident: e_1_3_3_1_2 doi: 10.1016/S0092-8674(01)00238-0 – ident: e_1_3_3_32_2 doi: 10.1093/ajcn/36.5.936 – ident: e_1_3_3_12_2 doi: 10.1161/atvb.19.6.1484 – ident: e_1_3_3_23_2 doi: 10.1016/S0002-9149(96)00159-2 – ident: e_1_3_3_27_2 doi: 10.1016/j.cll.2006.06.003 – ident: e_1_3_3_9_2 doi: 10.1161/01.cir.0000141728.23033.b5 – ident: e_1_3_3_17_2 doi: 10.1161/circulationaha.104.529297 – ident: e_1_3_3_6_2 doi: 10.1016/j.jacc.2006.03.001 – ident: e_1_3_3_28_2 doi: 10.1016/S1567-5688(02)00045-4 – ident: e_1_3_3_5_2 doi: 10.1056/NEJMoa043175 – ident: e_1_3_3_25_2 doi: 10.1001/jama.296.11.1363 – ident: e_1_3_3_19_2 doi: 10.1056/NEJMoa001066 – ident: e_1_3_3_7_2 doi: 10.1016/S0735-1097(02)02769-9 – ident: e_1_3_3_16_2 doi: 10.1016/j.atherosclerosis.2004.01.029 – ident: e_1_3_3_18_2 doi: 10.1194/jlr.M600109-JLR200 – ident: e_1_3_3_24_2 doi: 10.1161/circ.100.11.1154 – ident: e_1_3_3_31_2 doi: 10.1016/j.atherosclerosis.2004.07.030 – ident: e_1_3_3_4_2 doi: 10.1194/jlr.R400001-JLR200 – ident: e_1_3_3_14_2 doi: 10.1016/S0009-8981(00)00216-3 – ident: e_1_3_3_11_2 doi: 10.1016/j.jacc.2005.12.047 – ident: e_1_3_3_15_2 doi: 10.1016/j.cll.2006.06.004 – ident: e_1_3_3_8_2 doi: 10.1161/01.cir.0000130844.01174.55 – ident: e_1_3_3_2_2 doi: 10.1056/NEJMra043430 – ident: e_1_3_3_29_2 doi: 10.1074/jbc.270.52.31151 – ident: e_1_3_3_21_2 doi: 10.1093/clinchem/36.1.20 |
SSID | ssj0004220 |
Score | 2.3590758 |
Snippet | BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The... Background— Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The... Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of... |
SourceID | proquest pubmed pascalfrancis crossref wolterskluwer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1788 |
SubjectTerms | 1-Alkyl-2-acetylglycerophosphocholine Esterase - blood 1-Alkyl-2-acetylglycerophosphocholine Esterase - metabolism Age Factors Aged Apolipoprotein B-100 - blood Apolipoprotein B-100 - metabolism Atherosclerosis (general aspects, experimental research) Atherosclerosis - diagnosis Atherosclerosis - epidemiology Biological and medical sciences Biomarkers - blood Blood and lymphatic vessels Cardiology. Vascular system Coronary Artery Disease - enzymology Coronary Artery Disease - epidemiology Coronary Artery Disease - physiopathology Disease Progression Diseases of the cardiovascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Fundamental and applied biological sciences. Psychology General aspects Humans Male Medical sciences Middle Aged Phospholipases A2 Phospholipids - blood Phospholipids - metabolism Population Surveillance Predictive Value of Tests Probability Prognosis Proportional Hazards Models Prospective Studies Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Risk Factors Sensitivity and Specificity Severity of Illness Index Sex Factors Survival Analysis Vertebrates: cardiovascular system |
Title | Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17541022 https://www.proquest.com/docview/70752087 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiEkhLgJR9kHHkCtW6-ztnd5M1VQSikImqL2yfK1Imqwo8bm6E_iL_LCjL2-SlSOh1i25c3ams87h2e-IeQpH0UKZJsY-EkIQzeWIdXIMWI3AI0UBSouief33zqTQ_76yD4aDH52spaKPNyKzlbWlfyPVOEcyBWrZP9Bss2fwgnYB_nCFiQM27-S8btvs3h2Bibj4lO2hN98tpjFpWBgLyspGNDvF2AgynNnjUDLpTc6QJoSqyTY-KLbBWBgHRbR70j4E_WTV7Mih6fCuO3Iw4qDumpzA1z4Yp4v29qV8LRIk-ikQ2bbEN8iV3S2hAeD8RXfAXZu-BzWRzh_M6OmjGq0xO54Z_JGJ6upFucYohjvTnWqcZC2ycYHsFbveWW64kGWz3DqBnLe8YeqeiktdB1BHQ1xm1w8HQ1pWC06a7rpSsN2eG_RrwgJNLhFZwVnbtVmUFsDsF7ZqzWNg5rGm3586U28LYZxOm4L0271ap1LcE7dNkmQTEiObEOXyGULfBxsv7H3vkN1b1kVlYa--7riy2Hbv8_as6quAVrgBVdVZ5ZVrhNc8zXDbIzlSVmM0TGppjfIde0LUa8C9k0ySNJb5Mq-zva4TX7U-KY9fG_SDo6fBc97xx1c0x6uqWfRGtebFFBFNappH9W0RjV9QTuYphrTFDFNAdNUY5qWmL5DDl-NpzsTQ_cWMSIONr2hVMQF2G-uCGTIVABWKzj3jrRCaQrOFHND0zaVjBgLXRtpFWPbEnAJ44G07GR0l6ylWZrcJzQWI8USAX6ECjCeIIV0uIQJgkg4UvEhYbVs_EgT72P_l7lfOuAO87U84dj1K3kOyUYzZlHRzlx49XpP5O0QDbEheVJjwAf1gd8EgzTJiqXvgstgmcIdknsVNNqxrs0xHDQk2z2s-FWB9gW38-BPt_OQXG3f3UdkLT8tksdg2-fhevkO_AJLCf0R |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oxidized+phospholipids%2C+lipoprotein%28a%29%2C+lipoprotein-associated+phospholipase+A2+activity%2C+and+10-year+cardiovascular+outcomes+%3A+Prospective+results+from+the+bruneck+study&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=KIECHL%2C+Stefan&rft.au=WILLEIT%2C+Johann&rft.au=TSIMIKAS%2C+Sotirios&rft.au=MAYR%2C+Manuel&rft.date=2007-08-01&rft.pub=Lippincott&rft.issn=1079-5642&rft.volume=27&rft.issue=8&rft.spage=1788&rft.epage=1795&rft_id=info:doi/10.1161%2FATVBAHA.107.145805&rft.externalDBID=n%2Fa&rft.externalDocID=18940235 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |